{
    "nct_id": "NCT03630159",
    "official_title": "Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.",
    "inclusion_criteria": "* Confirmed DLBCL per local histopathology assessment.\n* Relapsed or refractory disease after having recieved 2 or more lines of systemic therapy, including anti-CD20 and anthracycline based chemotherapy, and either having progressed after (or relapsed after) ASCT, or being not candidates for or not consenting to ASCT.\n* Measurable disease at time of enrollment\n* ECOG performance status that is either 0 or 1 at screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with Richter's transformation, and Burkitt lymphoma, and primary DLBCL of CNS.\n* Prior treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy.\n* Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was >4 weeks before enrollment.\n* Prior allogeneic HSCT.\n* Unstable angina and/or myocardial infarction and/or coronary artery bypass graft (CABG), or stroke within 6 months prior to screening, and/or impaired cardiac function or clinically significant cardiac disease\n* Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibodies, other immune checkpoint inhibitors.\n* History of interstitial lung disease or (non-infectious) pneumonitis that required oral or intravenous steroids (other than COPD exacerbation) or current pneumonitis.\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}